Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

The US Food and Drug Administration (FDA) has approved Galderma's monoclonal antibody, Nemluvio (nemolizumab), for individuals aged 12 years and over with moderate-to-severe atopic dermatitis.

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label. Nemluvio (nemolizumab) – which was approved by the FDA in ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales. The US regulator cleared the IL-31 ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Dr. Navin Arora of Borealis Dermatology discusses new injectables EBGLYSS and Nemluvio for eczema patients as well as innovations in phototherapy. There are several new treatments for chronic ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...